BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lonardo A, Adinolfi LE, Restivo L, Ballestri S, Romagnoli D, Baldelli E, Nascimbeni F, Loria P. Pathogenesis and significance of hepatitis C virus steatosis: An update on survival strategy of a successful pathogen. World J Gastroenterol 2014; 20(23): 7089-7103 [PMID: 24966582 DOI: 10.3748/wjg.v20.i23.7089] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 59] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Nasheri N, Ning Z, Figeys D, Yao S, Goto NK, Pezacki JP. Activity-based profiling of the proteasome pathway during hepatitis C virus infection. Proteomics 2015;15:3815-25. [PMID: 26314548 DOI: 10.1002/pmic.201500169] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
2 Indolfi G, Guido M, Azzari C, Resti M. Histopathology of hepatitis C in children, a systematic review: implications for treatment. Expert Rev Anti Infect Ther. 2015;13:1225-1235. [PMID: 26202832 DOI: 10.1586/14787210.2015.1070668] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
3 Karlas T, Kollmeier J, Böhm S, Müller J, Kovacs P, Tröltzsch M, Weimann A, Bartels M, Rosendahl J, Mössner J, Berg T, Keim V, Wiegand J. Noninvasive characterization of graft steatosis after liver transplantation. Scand J Gastroenterol 2015;50:224-32. [PMID: 25429378 DOI: 10.3109/00365521.2014.983156] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
4 Hammerstad SS, Grock SF, Lee HJ, Hasham A, Sundaram N, Tomer Y. Diabetes and Hepatitis C: A Two-Way Association. Front Endocrinol (Lausanne). 2015;6:134. [PMID: 26441826 DOI: 10.3389/fendo.2015.00134] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 6.7] [Reference Citation Analysis]
5 ElDeeb MK, Ghazal AA, Metwally DE, Elghlied LA. Possible roles of methylenetetrahydrofolate reductase polymorphism and folate status in patients with early hepatitis C virus genotype 4. Arab J Gastroenterol 2021;22:121-6. [PMID: 33664006 DOI: 10.1016/j.ajg.2020.12.001] [Reference Citation Analysis]
6 Manickam C, Wachtman L, Martinot AJ, Giavedoni LD, Reeves RK. Metabolic Dysregulation in Hepacivirus Infection of Common Marmosets (Callithrix jacchus). PLoS One 2017;12:e0170240. [PMID: 28085952 DOI: 10.1371/journal.pone.0170240] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
7 Dyal HK, Aguilar M, Bhuket T, Liu B, Holt EW, Torres S, Cheung R, Wong RJ. Concurrent Obesity, Diabetes, and Steatosis Increase Risk of Advanced Fibrosis Among HCV Patients: A Systematic Review. Dig Dis Sci 2015;60:2813-24. [DOI: 10.1007/s10620-015-3760-3] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 6.0] [Reference Citation Analysis]
8 Kanda T, Moriyama M. Direct-acting antiviral agents against hepatitis C virus and lipid metabolism. World J Gastroenterol 2017; 23(31): 5645-5649 [PMID: 28883690 DOI: 10.3748/wjg.v23.i31.5645] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
9 Tiniakos DG, Anstee QM, Burt AD. Fatty Liver Disease. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 308-71. [DOI: 10.1016/b978-0-7020-6697-9.00005-4] [Cited by in Crossref: 7] [Article Influence: 1.8] [Reference Citation Analysis]
10 Galvin Z, Rajakumar R, Chen E, Adeyi O, Selzner M, Grant D, Sapisochin G, Greig P, Cattral M, McGilvray I, Ghanekar A, Selzner N, Lilly L, Patel K, Bhat M. Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis. Liver Transpl. 2019;25:56-67. [PMID: 30609189 DOI: 10.1002/lt.25338] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
11 Yair-Sabag S, Nussinson E, Ben-Assuli O, Shibli F, Shahbari A, Zelber-Sagi S. Retrospective study of the associations between hepatitis C virus infection and metabolic factors. World J Hepatol 2016; 8(30): 1269-1278 [PMID: 27843537 DOI: 10.4254/wjh.v8.i30.1269] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
12 Kahali B, Halligan B, Speliotes EK. Insights from Genome-Wide Association Analyses of Nonalcoholic Fatty Liver Disease. Semin Liver Dis 2015;35:375-91. [PMID: 26676813 DOI: 10.1055/s-0035-1567870] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 5.4] [Reference Citation Analysis]
13 Tsukiyama-Kohara K, Kohara M. Hepatitis C Virus: Viral Quasispecies and Genotypes. Int J Mol Sci 2017;19:E23. [PMID: 29271914 DOI: 10.3390/ijms19010023] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
14 Sagnelli C, Merli M, Uberti-Foppa C, Hasson H, Grandone A, Cirillo G, Salpietro S, Minichini C, Starace M, Messina E, Morelli P, Miraglia Del Giudice E, Lazzarin A, Coppola N, Sagnelli E. TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype. World J Gastroenterol 2016; 22(38): 8509-8518 [PMID: 27784963 DOI: 10.3748/wjg.v22.i38.8509] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
15 Abdelaziz AO, Shousha HI, Said EM, Soliman ZA, Shehata AA, Nabil MM, Abdelmaksoud AH, Elbaz TM, Abdelsalam FM. Evaluation of liver steatosis, measured by controlled attenuation parameter, in patients with hepatitis C-induced advanced liver fibrosis and hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2018;30:1384-8. [PMID: 30179227 DOI: 10.1097/MEG.0000000000001196] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Benedict M, Zhang X. Non-alcoholic fatty liver disease: An expanded review. World J Hepatol 2017; 9(16): 715-732 [PMID: 28652891 DOI: 10.4254/wjh.v9.i16.715] [Cited by in Crossref: 366] [Cited by in F6Publishing: 332] [Article Influence: 73.2] [Reference Citation Analysis]
17 Ferguson D, Zhang J, Davis MA, Helsley RN, Vedin LL, Lee RG, Crooke RM, Graham MJ, Allende DS, Parini P, Brown JM. The lipid droplet-associated protein perilipin 3 facilitates hepatitis C virus-driven hepatic steatosis. J Lipid Res 2017;58:420-32. [PMID: 27941027 DOI: 10.1194/jlr.M073734] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
18 Wójcik K, Piekarska A, Dąbrowicz A, Stasiak M, Gawryś K, Jabłonowska E. Hepatic Expression of Phosphorylated Kinase Akt and Glycogen Synthase Kinase-3 Isoforms in Patients with Chronic Hepatitis C. Viral Immunol 2019;32:179-85. [PMID: 31091179 DOI: 10.1089/vim.2018.0141] [Reference Citation Analysis]
19 Mihai C, Mihai B, Trifan A, Stanciu C, Gheorghe L, Diculescu M, Curescu M, Brisc C, Goldis A, Bataga S, Sandulescu L, Rogoveanu I, Seicean A, Cijevschi Prelipcean C. Metabolic Syndrome and Genotype 1 Virus C Compensated Liver Cirrhosis in the Era of Directly Acting Antiviral Therapy. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.58022] [Reference Citation Analysis]
20 Tu T, Bühler S, Bartenschlager R. Chronic viral hepatitis and its association with liver cancer. Biol Chem 2017;398:817-37. [PMID: 28455951 DOI: 10.1515/hsz-2017-0118] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 9.4] [Reference Citation Analysis]
21 Price JC, Ma Y, Scherzer R, Korn N, Tillinghast K, Peters MG, Noworolski SM, Tien PC. Human immunodeficiency virus-infected and uninfected adults with non-genotype 3 hepatitis C virus have less hepatic steatosis than adults with neither infection. Hepatology 2017;65:853-63. [PMID: 27981599 DOI: 10.1002/hep.28968] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
22 Shores NJ, Mendes-Corrêa MC, Maida I, Turner J, High KP, Babudieri S, Núãez M. Hepatic peroxisome proliferator-activated receptor γ and α-mRNA expression in HCV-infected adults is decreased by HIV co-infection and is also affected by ethnicity. Clinics (Sao Paulo) 2015;70:790-6. [PMID: 26735218 DOI: 10.6061/clinics/2015(12)05] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
23 Targher G, Lonardo A, Rossini M. Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link? J Endocrinol Invest 2015;38:817-25. [DOI: 10.1007/s40618-015-0315-6] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 7.4] [Reference Citation Analysis]
24 Zhao Y, Xing H. A Different Perspective for Management of Diabetes Mellitus: Controlling Viral Liver Diseases. J Diabetes Res 2017;2017:5625371. [PMID: 28352640 DOI: 10.1155/2017/5625371] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
25 Enomoto M, Nishiguchi S, Tamori A, Kozuka R, Fujii H, Uchida-Kobayashi S, Fukunishi S, Tsuda Y, Higuchi K, Saito M, Enomoto H, Kawada N. Sequential therapy involving an early switch from entecavir to pegylated interferon-α in Japanese patients with chronic hepatitis B. Hepatol Res 2018;48:459-68. [PMID: 29314465 DOI: 10.1111/hepr.13050] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
26 Chen Y, Cao D, Li C, Zhang P, Wang X, Li N, Han Q, Liu Z. A nomogram for discrimination of non-alcoholic fatty liver disease in patients with chronic hepatitis B. Eur J Gastroenterol Hepatol 2021;33:69-75. [PMID: 32118853 DOI: 10.1097/MEG.0000000000001691] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Vanni E, Bugianesi E, Saracco G. Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: Myth or reality? Digestive and Liver Disease 2016;48:105-11. [DOI: 10.1016/j.dld.2015.10.016] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 6.2] [Reference Citation Analysis]
28 Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, Targher G, Lonardo A. Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases. Metabolism. 2017;72:57-65. [PMID: 28641784 DOI: 10.1016/j.metabol.2017.04.003] [Cited by in Crossref: 75] [Cited by in F6Publishing: 75] [Article Influence: 15.0] [Reference Citation Analysis]
29 Ballestri S, Nascimbeni F, Romagnoli D, Baldelli E, Lonardo A. The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans. Adv Ther 2016;33:291-319. [PMID: 26921205 DOI: 10.1007/s12325-016-0306-9] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 9.5] [Reference Citation Analysis]
30 Cespiati A, Petta S, Lombardi R, Di Marco V, Calvaruso V, Bertelli C, Pisano G, Fatta E, Sigon G, Iuculano F, Crapanzano L, Gibilaro G, Francione P, Craxì A, Fargion S, Fracanzani AL. Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP). Dig Liver Dis 2020:S1590-8658(20)30997-X. [PMID: 33214063 DOI: 10.1016/j.dld.2020.11.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Conde I, Vinaixa C, Berenguer M. Hepatitis C-related cirrhosis. Current status. Med Clin (Barc) 2017;148:78-85. [PMID: 27855947 DOI: 10.1016/j.medcli.2016.09.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
32 Ding Y, Li G, Zhou Z, Deng T. Molecular mechanisms underlying hepatitis C virus infection-related diabetes. Metabolism 2021;121:154802. [PMID: 34090869 DOI: 10.1016/j.metabol.2021.154802] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Shousha HI, Abdelaziz RA, Azab SM, Khairy M, Afifi SA, Mehrez MI, Eshra MA, Abdelrahim AY. Effect of treatment with direct acting antivirals on body mass index and hepatic steatosis in chronic hepatitis C. J Med Virol 2018;90:1099-105. [PMID: 29469217 DOI: 10.1002/jmv.25062] [Reference Citation Analysis]
34 Lonardo A, Targher G. NAFLD: Is There Anything New under the Sun? Int J Mol Sci 2017;18:E1955. [PMID: 28895919 DOI: 10.3390/ijms18091955] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
35 Crisan D, Radu C, Suciu A, Leach N, Stefanescu H, Avram L, Crisan N, Grigorescu M. Hepatitis C in nonobese nondiabetic patients: Insulin resistance and the metabolic syndrome make a difference. J Viral Hepat 2017;24:86-7. [PMID: 27700001 DOI: 10.1111/jvh.12610] [Reference Citation Analysis]
36 Ballestri S, Nascimbeni F, Romagnoli D, Baldelli E, Targher G, Lonardo A. Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight. Int J Mol Sci. 2016;17:355. [PMID: 27005620 DOI: 10.3390/ijms17030355] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
37 Semmler G, Stift J, Scheiner B, Wöran K, Schwabl P, Paternostro R, Bucsics T, Stättermayer AF, Pinter M, Ferlitsch A, Trauner M, Reiberger T, Mandorfer M. Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension. Dig Dis Sci 2019;64:3642-51. [PMID: 31209721 DOI: 10.1007/s10620-019-05702-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
38 Hamoir C, Horsmans Y, Stärkel P, Dahlqvist G, Negrin Dastis S, Lanthier N. Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents. Acta Gastroenterol Belg 2021;84:25-32. [PMID: 33639690 DOI: 10.51821/84.1.420] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
39 Lonardo A, Ballestri S, Guaraldi G, Nascimbeni F, Romagnoli D, Zona S, Targher G. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol 2016; 22(44): 9674-9693 [PMID: 27956792 DOI: 10.3748/wjg.v22.i44.9674] [Cited by in CrossRef: 77] [Cited by in F6Publishing: 77] [Article Influence: 12.8] [Reference Citation Analysis]
40 Adinolfi LE, Rinaldi L, Guerrera B, Restivo L, Marrone A, Giordano M, Zampino R. NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. Int J Mol Sci. 2016;17. [PMID: 27231906 DOI: 10.3390/ijms17060803] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 7.2] [Reference Citation Analysis]
41 Wu YJ, Xu MY, Lu LG. Clinical Advances in Fibrosis Progression of Chronic Hepatitis B and C. J Clin Transl Hepatol 2014;2:222-7. [PMID: 26357628 DOI: 10.14218/JCTH.2014.00029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
42 Chaudhari R, Fouda S, Sainu A, Pappachan JM. Metabolic complications of hepatitis C virus infection. World J Gastroenterol 2021;27:1267-82. [PMID: 33833481 DOI: 10.3748/wjg.v27.i13.1267] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
43 Kupčová V, Fedelešová M, Bulas J, Kozmonová P, Turecký L. Overview of the Pathogenesis, Genetic, and Non-Invasive Clinical, Biochemical, and Scoring Methods in the Assessment of NAFLD. Int J Environ Res Public Health 2019;16:E3570. [PMID: 31554274 DOI: 10.3390/ijerph16193570] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
44 Ikura Y. Transitions of histopathologic criteria for diagnosis of nonalcoholic fatty liver disease during the last three decades. World J Hepatol 2014; 6(12): 894-900 [PMID: 25544876 DOI: 10.4254/wjh.v6.i12.894] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
45 Ciardullo S, Mantovani A, Ciaccio A, Carbone M, Invernizzi P, Perseghin G. Hepatitis C virus infection and diabetes: A complex bidirectional relationship. Diabetes Research and Clinical Practice 2022;187:109870. [DOI: 10.1016/j.diabres.2022.109870] [Reference Citation Analysis]
46 Pembroke T, Deschenes M, Lebouché B, Benmassaoud A, Sewitch M, Ghali P, Wong P, Halme A, Vuille-Lessard E, Pexos C, Klein MB, Sebastiani G. Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis. J Hepatol 2017;67:801-8. [PMID: 28527666 DOI: 10.1016/j.jhep.2017.05.011] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 8.0] [Reference Citation Analysis]
47 Lonardo A, Mantovani A. Clearing hepatitis C virus with direct antiviral agents reduces cardiovascular events in patients with prediabetes. Commentary to Sasso and colleagues. Nutr Metab Cardiovasc Dis 2021;31:2354-7. [PMID: 34154889 DOI: 10.1016/j.numecd.2021.05.019] [Reference Citation Analysis]
48 Kouroumalis E, Voumvouraki A. Hepatitis C virus: A critical approach to who really needs treatment. World J Hepatol 2022; 14(1): 1-44 [DOI: 10.4254/wjh.v14.i1.1] [Reference Citation Analysis]
49 Petta S. Hepatitis C virus and cardiovascular: A review. J Adv Res 2017;8:161-8. [PMID: 28149651 DOI: 10.1016/j.jare.2016.06.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
50 Yen YH, Kuo FY, Kee KM, Chang KC, Tsai MC, Hu TH, Lu SN, Wang JH, Hung CH, Chen CH. Diabetes is associated with advanced fibrosis and fibrosis progression in non-genotype 3 chronic hepatitis C patients. Dig Liver Dis 2019;51:142-8. [PMID: 30076015 DOI: 10.1016/j.dld.2018.07.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
51 Trifan A, Stratina E, Rotaru A, Stafie R, Zenovia S, Nastasa R, Huiban L, Sfarti C, Cojocariu C, Cuciureanu T, Muzica C, Chiriac S, Girleanu I, Singeap A, Stanciu C. Changes in Liver Steatosis Using Controlled Attenuation Parameter among Patients with Chronic Hepatitis C Infection Treated with Direct-Acting Antivirals Therapy Who Achieved Sustained Virological Response. Diagnostics 2022;12:702. [DOI: 10.3390/diagnostics12030702] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Siphepho PY, Liu YT, Shabangu CS, Huang JF, Huang CF, Yeh ML, Yu ML, Wang SC. The Impact of Steatosis on Chronic Hepatitis C Progression and Response to Antiviral Treatments. Biomedicines 2021;9:1491. [PMID: 34680608 DOI: 10.3390/biomedicines9101491] [Reference Citation Analysis]
53 Nirei K, Matsumura H, Kumakawa M, Matsumoto N, Nakamura H, Yamagami H, Matsuoka S, Moriyama M. Steatosis influences the clinical profiles and long-term outcomes of interferon-treated chronic hepatitis C and liver cirrhosis patients. Int J Med Sci 2017;14:45-52. [PMID: 28138308 DOI: 10.7150/ijms.17202] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
54 Villareal VA, Fu D, Costello DA, Xie XS, Yang PL. Hepatitis C Virus Selectively Alters the Intracellular Localization of Desmosterol. ACS Chem Biol 2016;11:1827-33. [PMID: 27128812 DOI: 10.1021/acschembio.6b00324] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
55 Kralj D, Virović Jukić L, Stojsavljević S, Duvnjak M, Smolić M, Čurčić IB. Hepatitis C Virus, Insulin Resistance, and Steatosis. J Clin Transl Hepatol 2016;4:66-75. [PMID: 27047774 DOI: 10.14218/JCTH.2015.00051] [Cited by in Crossref: 57] [Cited by in F6Publishing: 35] [Article Influence: 9.5] [Reference Citation Analysis]
56 Rattansingh A, Amooshahi H, Menezes RJ, Wong F, Fischer S, Kirsch R, Atri M. Utility of shear-wave elastography to differentiate low from advanced degrees of liver fibrosis in patients with hepatitis C virus infection of native and transplant livers. J Clin Ultrasound 2018;46:311-8. [PMID: 29508406 DOI: 10.1002/jcu.22583] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
57 Piacentini M, Baiocchini A, Del Nonno F, Melino G, Barlev NA, Rossin F, D'Eletto M, Falasca L. Non-alcoholic fatty liver disease severity is modulated by transglutaminase type 2. Cell Death Dis 2018;9:257. [PMID: 29449533 DOI: 10.1038/s41419-018-0292-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
58 Modaresi Esfeh J, Ansari-Gilani K. Steatosis and hepatitis C. Gastroenterol Rep (Oxf) 2016;4:24-9. [PMID: 26276502 DOI: 10.1093/gastro/gov040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
59 Roger S, Ducancelle A, Le Guillou-Guillemette H, Gaudy C, Lunel F. HCV virology and diagnosis. Clin Res Hepatol Gastroenterol 2021;45:101626. [PMID: 33636428 DOI: 10.1016/j.clinre.2021.101626] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]